Hemophilia B and free tissue transfer: Medical and surgical management

Annals of Plastic Surgery

Volumn 54, Issue 3, 2005, Pages 336-338

  Knott, P Daniel ^a   Khariwala, Samir S ^a   Minarchek, Joseph ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b GRANT MEDICAL CENTER   (United States)

Author keywords

Bleeding disorder; Blood dyscrasia; Hemophilia; Microvascular free tissue transfer; Reconstructive surgery

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 9;

AGED; ARTICLE; BLEEDING DISORDER; BLOOD DYSCRASIA; CASE REPORT; DISEASE SEVERITY; FREE TISSUE GRAFT; HEMOPHILIA; HEMOPHILIA B; HEMOSTASIS; HUMAN; MALE; MICROVASCULAR SURGERY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SURGICAL PATIENT; THROMBOSIS; X CHROMOSOME LINKED DISORDER;

AGED; HEMOPHILIA B; HUMANS; KNEE; MALE; MUSCLE, SKELETAL; RECONSTRUCTIVE SURGICAL PROCEDURES; SURGICAL FLAPS;

EID: 14044259401     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sap.0000141050.91794.b4     Document Type: Article

References (11)

1. Bolton-Maggs PHB, Pasi KJ. Hemophilias A and B. Lancet. 2003;361: 1801-1809.
2. White GC II, Rosendaal F, Aledort LM, et al. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Hemostasis. Thromb Haemost. 2001;85: 560-568.
3. Lowe GDO. Overview: factor IX and thrombosis. Br J Haematol. 2001;115:507-513.
4. Lillicrap D. The molecular basis of haemophilia B. Haemophilia. 1998: 4:350-357.
5. United Kingdom Haemophilia Centre Doctors' Organization. Guidelines on the selection and use of therapeutic products to treat hemophilia and other hereditary bleeding disorders. Haemophilia. 2003;9:1-23.
6. Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002;8:280-287.
7. Roth DA, Kessler CM, Pasi J, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98:3600-3606.
8. Fischer K, Van der bom JG, Prejs R. et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia. 2001;7:544-550.
9. Fischer K, Astermark J, Van der bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia. 2002;8:753-760.
10. Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmokinetic perspective. Haemophilia. 2003;9(suppl 1):101-108.
11. Vandendriessche D, Collen D, Chuah MKL. Gene therapy for the hemophilias. J Thromb Haemost. 2003;1:1550-1558.